Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 19

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 19
---
 virtue of their exclusive ownership of our Class A Common Stock. |

In addition, our credit facility includes, and
other debt instruments we may enter into in the future may include, provisions entitling the lenders to demand immediate repayment of
all borrowings upon the occurrence of certain change of control events relating to our company, which also could discourage, delay or
prevent a business combination transaction.

The Company is not subject to Section 203
of the Delaware General Corporation Law (the “DGCL”). In general, Section 203 may prohibit large stockholders, in particular
those owning 15% or more of our outstanding voting stock, from merging or combining with us for a period of time without the approval
of our board of directors. The Company elected to “opt out” of the provisions of Section 203 of the Delaware General
Corporation Law (the “DGCL”) in the Third Amended and Restated Certificate of Incorporation.

Transfer Agent and Registrar

The transfer agent and registrar for our common
stock is VStock Transfer, LLC.

Stock Market Listing

Our common stock is listed on The Nasdaq Capital
Market under the symbol “DERM.”

<div align='center'>S-12

PLAN OF DISTRIBUTION</div>

We have entered into a Sales Agreement with the
Agents, under which we may issue and sell from time to time up to 3,750,000 shares of our common stock through or to the Agents, each
acting as sales agent or principal. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be
“at the market” as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on any trading
market for our common stock. If authorized by us in writing, the Agents may purchase shares of our common stock as principal.

The Agents will offer our common stock subject
to the terms and conditions of the Sales Agreement on a daily basis or as otherwise agreed upon by us and the Agents. We will designate
the maximum amount of common stock to be sold through the Agents on a daily basis or otherwise determine such maximum amount together
with the Agents. Subject to the terms and conditions of the Sales Agreement, the Agents will use their commercially reasonable efforts
to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct the Agents not to sell common stock
if the sales cannot be effected at or above the price designated by us in